CN102940655B - Medicine composition for treating benign prostatic hyperplasia - Google Patents
Medicine composition for treating benign prostatic hyperplasia Download PDFInfo
- Publication number
- CN102940655B CN102940655B CN201210428028.6A CN201210428028A CN102940655B CN 102940655 B CN102940655 B CN 102940655B CN 201210428028 A CN201210428028 A CN 201210428028A CN 102940655 B CN102940655 B CN 102940655B
- Authority
- CN
- China
- Prior art keywords
- prostatic hyperplasia
- medicine composition
- aspongopus
- radix angelicae
- angelicae sinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine composition for treating benign prostatic hyperplasia (BPH), comprising aspongopus and Angelica sinensis. The medicine composition disclosed herein can rapidly alleviate the clinical symptoms of BPH patients, and can reduce the prostate volume, and the price is low, and there is no side effect.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of prostatic hyperplasia, relate to specifically a kind of pharmaceutical composition for the treatment of prostatic hyperplasia.
Background technology
Hyperplasia of prostate (BPH) is the common disease of elderly men, and its sickness rate increases with the increase at age, according to reports, China's more than 60 years old elderly men population has reached 1.5 hundred million people, sickness rate by 60% is calculated, and adds and suffers from the past BPH person in 60 years old, and China approximately has 100,000,000 people to suffer from BPH at present.
BPH can cause that controlled micturition difficulty, difficulty in micturition, urine urgency-frequency, nocturia increase etc., further develops complication such as can causing serious urinary tract infection, vesical calculus, hematuria, urine retention, kidney merit decline, inguinal hernia, has a strong impact on patient's quality of life.
The treatment means of BPH is a lot, but the various means of domestic and international existing treatment BPH run into following thorny problem: operative treatment is with certain traumatic, and complication is many, and old people is poor to the toleration of operation and anesthesia.Naturopathy, as the relief of symptoms in a short time such as microwave, radio frequency, high-energy focusing, also has the complication such as urethral stricture.Dwindle the medicine of prostate volume as finasteride (proscar), can make prostate volume dwindle, but price more expensive (9 yuan/day), and slow (onset in March) of onset; And can cause the side effect such as hyposexuality, sexual impotence.
Though research at present has the Chinese patent medicine of some treatment hyperplasia of prostates, but still can not meet patient's needs, and its prescription composition is all more complicated, flavour of a drug are more, and price is higher, unsatisfactory curative effect.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition prostatic hyperplasia, determined curative effect for the treatment of.The pharmaceutical composition for the treatment of prostatic hyperplasia of the present invention can comparatively fast be alleviated BPH patient's clinical symptoms, can dwindle prostate volume again, and low price, has no side effect.
To achieve these goals, technical scheme provided by the invention is:
Treat a pharmaceutical composition for prostatic hyperplasia, it is by Aspongopus with when being classified as the medicament that medicinal raw material is made.
The weight proportion of pharmaceutical composition of the present invention medicine material used can be: 3 one 15 parts of Aspongopuss, 3-15 parts of Radix Angelicae Sinensis.
More preferably the proportioning of pharmaceutical composition of the present invention medicine material used is: 6-12 parts of Aspongopuss, 6-12 parts of Radix Angelicae Sinensis.
The best proportioning of pharmaceutical composition of the present invention medicine material used is: 9 parts of Aspongopuss, 9 parts of Radix Angelicae Sinensis.
Medicine of the present invention can be prepared into said dosage form on any pharmaceutics, can be any existing pharmaceutical dosage form in injection, transfusion, powder pin, drop pill, tablet, slow releasing tablet, capsule, soft capsule, granule.
Pharmaceutical composition of the present invention can adopt but be not limited to following methods:
(1) get Aspongopus fragmentation, add 70% ethanol extraction of 8-10 times of volume, extract 3 times, each 1.5-2h, collects merge extractive liquid, concentrated, dry, obtains Aspongopus extract.
(2) get Radix Angelicae Sinensis medical material, water percolation, collects percolate, and percolate, by macroporous adsorbent resin, is first washed with water, removes the impurity that is dissolved in polar solvent, and this water elution liquid is discarded; Use again 80% high concentration ethanol eluting, collect this high concentration ethanol eluent, the eluent reclaiming after ethanol is dried, obtain Radix Angelicae Sinensis extract.
(3) said extracted thing is mixed, make acceptable various pharmaceutical dosage form.
In above preparation process, if necessary, can add adjuvant conventional in appropriate pharmaceutics, as starch, dextrin, microcrystalline cellulose, amylum pregelatinisatum, magnesium stearate, micropowder silica gel, sucrose, carboxymethyl starch sodium etc.
Solution of the present invention is the pathogenetic understanding to BPH based on motherland's medical science, according to oneself clinical experience for many years, first from numerous Chinese medicine, determines the effective Chinese medicine of a series for the treatment of BPH, more repeatedly verifies through clinical, screens.In pharmaceutical composition of the present invention, Aspongopus salty in the mouth, warm in nature, returns Liver Channel, kidney channel, spleen channel, has the function of promoting the circulation of QI to relieve pain, warming the kidney to invigorate YANG.Radix Angelicae Sinensis sweet in the mouth, pungent, bitter, returns liver, the heart, spleen channel, has the function of enriching blood, invigorating blood circulation.Aspongopus, Radix Angelicae Sinensis share, promoting flow of QI and blood, and warming the kidney to invigorate YANG, can comparatively fast alleviate BPH controlled micturition difficulty symptom and remove its misery, can dwindle prostate volume again and delays its disease progression, and low price, have no side effect.
The present invention's various raw medicinal materials used are and meet the Chinese crude drug that country or provincial standard specify.
Compared with prior art, the invention has the beneficial effects as follows: clinical drug of the present invention uses result to show there is following advantage:
(1) can treat the symptoms such as nocturia that BPH causes, dysuria, lower abdomen distension, reduce international prostate gland symptoms scoring (I-PSS scoring), improve the quality of living.
(2) obviously improve urine flow rate.
(3) obviously reduce residual urine volume.
(4) have no side effect.
(5) stable curative effect.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is described in further detail.
Embodiment 1
The pharmaceutical composition of the treatment prostatic hyperplasia that the present embodiment is enumerated, is made up of the medicinal raw material of following weight: Aspongopus 9g, Radix Angelicae Sinensis 9g.
Above-mentioned medicinal raw material is prepared into soft capsule, and preparation method is as follows:
(1) get Aspongopus fragmentation by formula proportion, add 70% ethanol extraction of 10 times of volumes, extract 3 times, each 2h, collects merge extractive liquid, concentrated, dry, obtains Aspongopus extract.
(2) get Radix Angelicae Sinensis medical material by formula proportion, water percolation, collects percolate, and percolate, by macroporous adsorbent resin, is first washed with water, removes the impurity that is dissolved in polar solvent, and this water elution liquid is discarded; Use again 80% high concentration ethanol eluting, collect this high concentration ethanol eluent, the eluent reclaiming after ethanol is dried, obtain Radix Angelicae Sinensis extract.
(3) said extracted thing is mixed, add vegetable oil 10g, mix, make capsule casing material with gelatin, be pressed into soft capsule.
Embodiment 2
The pharmaceutical composition of the treatment prostatic hyperplasia that the present embodiment is enumerated, is made up of the medicinal raw material of following weight: Aspongopus 3g, Radix Angelicae Sinensis 3g.
Above-mentioned medicinal raw material is prepared into injectable powder, and preparation method is as follows:
(1) get Aspongopus fragmentation by formula proportion, add 70% ethanol extraction of 8 times of volumes, extract 3 times, each 1.5h, collects merge extractive liquid, concentrated, dry, obtains Aspongopus extract.
(2) get Radix Angelicae Sinensis medical material by formula proportion, water percolation, collects percolate, and percolate, by macroporous adsorbent resin, is first washed with water, removes the impurity that is dissolved in polar solvent, and this water elution liquid is discarded; Use again 80% high concentration ethanol eluting, collect this high concentration ethanol eluent, the eluent reclaiming after ethanol is dried, obtain Radix Angelicae Sinensis extract.
(3) said extracted thing is mixed, be dissolved in 1000mL water for injection, adopt existing preparation of injection, make injectable powder.
Embodiment 3
The pharmaceutical composition of the treatment prostatic hyperplasia that the present embodiment is enumerated, is made up of the medicinal raw material of following weight: Aspongopus 15g, Radix Angelicae Sinensis 15g.
Above-mentioned medicinal raw material is prepared into capsule, and preparation method is as follows:
(1) get Aspongopus fragmentation by formula proportion, add 70% ethanol extraction of 10 times of volumes, extract 3 times, each 2h, collects merge extractive liquid, concentrated, dry, obtains Aspongopus extract.
(2) get Radix Angelicae Sinensis medical material by formula proportion, water percolation, collects percolate, and percolate, by macroporous adsorbent resin, is first washed with water, removes the impurity that is dissolved in polar solvent, and this water elution liquid is discarded; Use again 80% high concentration ethanol eluting, collect this high concentration ethanol eluent, the eluent reclaiming after ethanol is dried, obtain Radix Angelicae Sinensis extract.
(3) said extracted thing is mixed, 120g is mixed homogeneously with starch, adopts capsules preparation technique, makes the pharmaceutical composition of capsule.
For showing clinical effectiveness of the present invention, with reference to " new Chinese medicine guideline of clinical investigations " (1997), select 50 years old above, to be diagnosed as prostatic hyperplasia patient's 30 example, carry out the objective clinical observation of system.One month observation period.Instructions of taking: take the obtained medicament of embodiment 1,10g/ day, points 3 times oral.Respectively at before taking medicine and take observation post administration:
(1) safety indexes: blood pressure, pulse, blood, urine, the large routine of excrement three and electrocardiogram, liver, kidney brake check.
(2) health giving quality index:
(a) urine flow rate inspection: Qmax, AFR detect.
(b) residual urine volume is measured: adopt through abdomen B ultrasonic method.
(c) prostate volume detects: adopt per rectum B ultrasonic method.
(3) untoward reaction is observed:
Comprise that gastrointestinal reaction, nervous system abnormality, skin and muscle are abnormal etc.
Before and after treatment, indices changes as shown in table 1～4
The international prostate gland symptoms scoring of table 1 (I-PSS) and quality of life index (QOL) change
note:
*represent self cross-reference p>0.05,
*represent and the front relatively p<0.05 for the treatment of,
* *before expression and treatment, compare under p<0.01(same).
Table 2 Qmax (MFR), AFR (AFR) are relatively
Note: p value representation is the same.
Table 3 residual urine volume (PVR) relatively
Note: p value representation is the same.
Table 4 prostate volume (ml) relatively
Note: p value representation is the same.
Above-mentioned clinical observation result shows, pharmaceutical composition of the present invention can be alleviated the clinical symptoms of prostatic hyperplasia, dwindles prostate volume, improves patient's quality of life.
In drug administration process, have no obvious adverse reaction, electrocardiogram before and after taking medicine, liver, renal function, blood, routine urinalysis are without significant change.
Claims (3)
1. a pharmaceutical composition for prostatic hyperplasia, is characterized in that: it is to be made up of the crude drug of following weight parts proportioning:
Aspongopus 3-15 part, Radix Angelicae Sinensis 3-15 part.
2. Chinese medicine composition according to claim 1, is characterized in that: the weight portion proportioning of described each crude drug is:
Aspongopus 6-12 part, Radix Angelicae Sinensis 6-12 part.
3. Chinese medicine composition according to claim 2, is characterized in that: the weight portion proportioning of described each crude drug is:
9 parts of Aspongopuss, 9 parts of Radix Angelicae Sinensis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210428028.6A CN102940655B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating benign prostatic hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210428028.6A CN102940655B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating benign prostatic hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102940655A CN102940655A (en) | 2013-02-27 |
| CN102940655B true CN102940655B (en) | 2014-11-26 |
Family
ID=47723715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210428028.6A Active CN102940655B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating benign prostatic hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102940655B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106421125A (en) * | 2016-11-29 | 2017-02-22 | 佘延英 | Traditional Chinese medicine for treating prostatic hyperplasia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732660A (en) * | 2009-12-25 | 2010-06-16 | 卢速江 | Chinese medicinal preparation for treating prostate disease and preparation method thereof |
-
2012
- 2012-10-31 CN CN201210428028.6A patent/CN102940655B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732660A (en) * | 2009-12-25 | 2010-06-16 | 卢速江 | Chinese medicinal preparation for treating prostate disease and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 刘正才.前列腺肥大.《常见慢性病饮食调养法》.江西科学技术出版社,2006,第161-162页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102940655A (en) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101491572A (en) | Medicine for treating calculus and preparation method thereof | |
| CN101103989A (en) | Medicinal composition for promoting enterogastric peristalsis | |
| CN105998297A (en) | Traditional Chinese medicine composition with effects of moistening intestines and relaxing bowels and preparation method thereof | |
| CN102225181B (en) | Medicament for treating benign prostatic hyperplasia disease and preparation method thereof | |
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN102772611B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN102940655B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN102940750B (en) | Medicine composition for treating gout | |
| CN102940656B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN102940674B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN103585449A (en) | Traditional Chinese medicine composition for treating migraine | |
| CN103386101B (en) | Traditional Chinese medicine preparation for nonspecific cystitis treatment and preparation method thereof | |
| CN102940692B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN102940681A (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN102139060B (en) | Chinese medicinal composition for treating acute urarthritis | |
| CN100435840C (en) | Medicament for treating hyperplasia of prostate | |
| CN103860601B (en) | A kind of Chinese medicine composition treating prostatic hyperplasia | |
| CN104127684A (en) | Traditional Chinese medicine compound preparation for treating cancers | |
| CN103768129A (en) | Drug composition for preventing or treating hypertension | |
| CN114246931B (en) | External application preparation for treating winter diseases in summer and preparation method thereof | |
| CN102824573B (en) | Medicine for treating prostatic diseases | |
| CN102961680B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof | |
| CN106266989A (en) | A kind of Chinese medicine composition for treating caused by energy stagnation and blood stasis hysteromyoma | |
| CN104800622A (en) | Traditional Chinese medicine ointment for treating chronic constipation and anorectal diseases as well as preparation method of traditional Chinese medicine ointment | |
| CN102961678B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170621 Address after: 810000 No. 18, Dongxin Road, Xining economic and Technological Development Zone, Qinghai Patentee after: Qingdao Reach Pharmaceutical (Group) Co., Ltd. Address before: Science Park high tech Zone of Chengdu South Road, No. 88 610041 Sichuan province Tianfu Life Science Park building B6 No. 9 Patentee before: Chengdu Yilukang Medical Technology & Service Co., Ltd. |